Stay updated on BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Sign up to get notified when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.

Latest updates to the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed.SummaryDifference0.0%

- Check21 days agoChange DetectedRemoved the government funding/operating-status notice from the page.SummaryDifference0.3%

- Check42 days agoChange DetectedAdded Cali, Colombia as a study site and removed Santiago de Cali, Colombia from the locations. This updates the study's site list and may affect participant access and logistics.SummaryDifference0.4%

- Check64 days agoChange DetectedMajor update: adds an operating-status notice and updates version to v3.2.0; removes the Follicular lymphoma resource (from GRDIC).SummaryDifference4%

- Check71 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check85 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top link was removed. No substantive content changes are evident.SummaryDifference0.2%

Stay in the know with updates to BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.